The US Food and Drug Administration has approved the new drug Cobenfy, which is owned by pharmaceutical firm Bristol Myers ...
Schizophrenia causes persistent delusions and hallucinations and significantly impairs the way patients perceive reality.
The US Food and Drug Administration has granted approval to Bristol-Myers Squibb’s drug Cobenfy® (xanomeline and trospium ...
KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually. The drug represents a new way to treat adults with schizophrenia.
Bristol Myers Squibb stock jumped after the pharma company won approval for its new schizophrenia drug late Thursday. “This ...
Scientists have said a new schizophrenia drug "has the potential to change the lives of millions of people". The US Food and Drug Administration (FDA) has approved the new drug Cobenfy, which is owned ...
Bristol-Myers Squibb won Food and Drug Administration approval late Thursday for its novel schizophrenia drug, Cobenfy. BMY ...
Gemma Collins appeared on Who Do You Think You Are? to find answers about what became of her gran after her mum was placed in ...
The Bristol Myers Squibb medicine is said relieve symptoms without causing some of the harsh side effects of drugs already in use. Meanwhile, thousands of patients allege in a lawsuit that drugs used ...